1. Home
  2. RDHL

RDHL

Redhill Biopharma Ltd.

Logo Redhill Biopharma Ltd.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-19-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.

Founded: 2009 Country:
Israel
Israel
Employees: N/A City: N/A
Market Cap: 13.7M IPO Year: N/A
Target Price: N/A AVG Volume (30 days): 1.2M
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: 4.00 EPS Growth: N/A
52 Week Low/High: $0.26 - $3.60 Next Earning Date: 04-08-2024
Revenue: $6,530,000 Revenue Growth: -90.81%
Revenue Growth (this year): 224.9% Revenue Growth (next year): 82.69%

Share on Social Networks: